Electra Therapeutics Receives FDA Breakthrough Therapy and EMA PRIME Designations for ELA026 in sHLH
Electra, a clinical-stage biotechnology company developing novel treatments for immune and cancer-related diseases, announced that its lead candidate ELA026 has granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH).
ELA026 is the first investigational therapy for sHLH to receive both designations, highlighting its potential to address a critical unmet medical need in this life-threatening condition.
The recognitions were based on positive Phase 1b clinical data, where ELA026 demonstrated rapid disease control and clinical improvement in patients with malignancy-associated HLH, the subgroup with the poorest prognosis.
Treatment achieved 100% overall survival at eight weeks, 100% response rate by week four, and 100% hospital discharge, alongside strong biomarker evidence of inflammation reduction.
Electra’s SURPASS trial (NCT05416307), a global pivotal Phase 2/3 study, is now enrolling patients across the U.S. and Europe.
The FDA’s Breakthrough Therapy and EMA PRIME designations are designed to expedite the development and review of promising treatments for serious or life-threatening diseases, enabling enhanced regulatory guidance and potential accelerated approval pathways.
